We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Stem Cell Therapy Cures Diabetes in Mouse Model

By LabMedica International staff writers
Posted on 08 Feb 2015
Diabetes researchers modified human skin cells to produce insulin and showed that after being injected into diabetic immunodeficient mice, the cells developed into an insulin-producing organoid capable of modulating the animals' glucose metabolism.

In type I diabetes, the individual's immune system attacks and destroys the pancreatic beta cells that produce insulin. More...
While pancreas transplants from cadavers can be used to treat the disorder, the very small number of available organs limits usefulness of this method.

In a different approach, investigators at the University of Iowa (Iowa City, USA) modified human skin cells to create induced pluripotent stem (iPS) cells. The undifferentiated iPS cells were subjected to differentiation using a multistep protocol to generate insulin producing cells (IPCs) in vitro. The successful differentiation of human iPS cells into IPCs was validated by real-time quantitative PCR, immunostaining, transmission electron microscopy, and mitochondria stress tests.

The IPCs were injected into streptozotocin-induced diabetic immunodeficient mice under the kidney capsule, a thin membrane layer that surrounds the kidney. The real-time fate of the transplanted IPCs was monitored by MRI, which revealed the presence of an organoid on the kidneys of the mice that received IPCs. These organoids showed neo-vascularization and stained positive for insulin and glucagon. The animals' serum glucose levels gradually declined to either normal or near normal levels over 150 days, suggesting that the IPCs were secreting insulin. Furthermore, none of the mice that had received IPCs developed tumors from the transplanted stem cells.

"This raises the possibility that we could treat patients with diabetes with their own cells," said senior author Dr. Nicholas Zavazava, professor of internal medicine at the University of Iowa. "That would be a major advance, which will accelerate treatment of diabetes."

The study was published in the January 28, 2015, online edition of the journal PLOS ONE.

Related Links:

University of Iowa



New
Gold Member
Automatic Hematology Analyzer
CF9600
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.